Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • Axsome Therapeutics' Change in Receivables fell 16174.75% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year increase of 5851.45%. This contributed to the annual value of $47.2 million for FY2024, which is 1740.17% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Change in Receivables is -$2.3 million, which was down 16174.75% from $37.4 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Change in Receivables high stood at $37.4 million for Q2 2025, and its period low was -$2.3 million during Q3 2025.
  • In the last 4 years, Axsome Therapeutics' Change in Receivables had a median value of $16.4 million in 2023 and averaged $13.9 million.
  • Over the last 5 years, Axsome Therapeutics' Change in Receivables had its largest YoY gain of 19321.24% in 2025, and its largest YoY loss of 16174.75% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Change in Receivables (Quarter) stood at $17.4 million in 2022, then fell by 5.7% to $16.4 million in 2023, then grew by 9.14% to $17.9 million in 2024, then tumbled by 112.95% to -$2.3 million in 2025.
  • Its Change in Receivables stands at -$2.3 million for Q3 2025, versus $37.4 million for Q2 2025 and $19.4 million for Q1 2025.